Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype

ConclusionsIn real life, PAH-LHD patients are frequent, have less severe disease and are less likely treated with PAH drug combinations than no-LHD. The  COMPERA 2.0 model may be more appropriate to evaluate their mortality risk during follow-up and how it is modulated by therapy.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research